Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04542889
Other study ID # APHP190831
Secondary ID 2019-A02413-54
Status Terminated
Phase N/A
First received
Last updated
Start date September 7, 2020
Est. completion date June 26, 2021

Study information

Verified date April 2024
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the management of acute myocardial infarction treated with primary angioplasty, despite effective epicardial clearance obtained in 95% of cases, microvascular obstruction (MVO) in the damaged territory concerns 50% of patients. The Index of Microvascular Resistance (IMR) allows early assessment of the microcirculatory state during the angioplasty procedure. A value of IMR>40 indicates MVO and is correlated with morbi-mortality. A new method for immediate evaluation of MVO using thermodilution with a new Rayflow® microcatheter has been described: it no longer allows the estimation but the measurements of absolute coronary resistance and coronary flow. We hypothesize that these measurements allows a better evaluation of the microcirculatory state after primary angioplasty, comparing to IMR. The main objective is to study the diagnostic performance of Rayflow® to predict MVO - no reflow (NR) - in ST-Elevation Myocardial Infarction (STEMI) patients in order to determine an absolute coronary resistance threshold by thermodilution for early diagnosis of MVO. The main secondary objectives will be to compare the different microcirculatory assessment parameters with each other, not indexed and indexed to the myocardial mass at risk (coronary resistance, IMR, CFR, Resistance Reserve Ratio) and to establish a link between high resistance or IMR and the occurrence of rhythm disorders at D1, D2 and D3.


Description:

All patients presenting for STEMI by occlusion of a proximal coronary artery, vascularizing a large volume of myocardium corresponding to an APPROACH score> 21, in the first 12 hours following the onset of chest pain, will be included. Data relating to medical history, lifestyle (sedentary lifestyle, smoking, drug use), cardiovascular risk factors will be collected. The management of acute coronary syndrome will be carried out in accordance with the European Society of Cardiology guidelines of 2015. An emergency coronary angiography will be used to revascularise the patient as indicated. Thromboaspiration, stenting, antithrombotic agents and other treatments will be administered according to angiographic and clinical criteria. The FFR guide (PressureWire® Certus® from St Jude Medical Abbott) will be used to make pressure and temperature measurements. It has been used in daily practice since the FAME study in 2011 to guide the therapeutic decision in patients with an intermediate lesion. An injected cardiac magnetic resonance imaging (MRI) will be performed between 48 hours and 7 days following the infarction in accordance with current practices.The initial trans-thoracic ultrasonography as well as the various blood samplings will be performed according to standard practice. The Rayflow® microcatheter will be used to allow the optimal delivery of physiological saline solution into the studied artery. It will be mounted on the FFR guide already in place as part of the angioplasty procedure. Bayer's Medrad® Mark 7 Arterion® infuser will be used to deliver saline continuously at a flow rate of 15-20 mL/min through the Rayflow® microcatheter


Recruitment information / eligibility

Status Terminated
Enrollment 31
Est. completion date June 26, 2021
Est. primary completion date June 26, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Acute ST + coronary syndrome seen within 12 hours after the initial pain: ST offset in 2 contiguous leads = 1mm or = 2mm in precordial or inaugural left branch block, permanent or transient with chest pain > 20 min - Patient with an indication for emergency coronary angiography with angioplasty - Acute occlusion of a large caliber artery corresponding to an APPROACH score =21: proximal or mean anterior interventricular artery, proximal circumflex artery or proximal right coronary artery - Final Thrombolysis In Myocardial Infarction (TIMI) of 2 or 3 at the end of the angioplasty procedure regardless of the initial TIMI score - Free and informed written consent to participate in the study Exclusion Criteria: - Known history of infarction in the same territory : STEMI or NSTEMI (angioplasty programmed for angina does not constitute a criterion for non-inclusion) - Haemodynamic instability requiring the initial use of vasopressive amines or circulatory assistance (counterpulse balloon or extracorporeal membrane oxygenation) or mechanical ventilation (a recovered cardiopulmonary arrest does not constitute an exclusion criterion) - Technical impossibility of performing IMR or Rayflow® measurements (tortuous or calcified artery) - Persistent high-grade atrioventricular block after primary angioplasty - Cardiomyopathy or severe valvulopathy which can induce microcirculatory abnormalities (congenital heart diseases, dilated cardiomyopathy, cardiac amyloidosis, hypertrophic heart disease, mitral regurgitation, aortic regurgitation, tricuspid regurgitation or pulmonary regurgitation grade 3 or 4, tight aortic stenosis or pulmonary stenosis with average gradient > 40 mmHg or vmax > 4m/sec , tight mitral stenosis or tricuspid stenosis with average gradient > 10mmHg) - Contraindication to performing cardiac MRI: wearing a pacemaker, intracerebral clip, intraocular foreign body, neurostimulator, severe renal failure with glomerular filtration rate < 30 mL/min, body weight > 150 kg - Age < 18 years - Pregnant or breastfeeding woman - Inclusion in another research protocol < 30 days - Patient not affiliated to a social security scheme - Patient under guardianship or curatorship

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Absolute coronary flow and resistance measurements
Thermodilution-based measurements of absolute coronary resistances using the FFR pressure guide (PressureWire® Certus® from St Jude Medical Abbott) and the Rayflow® microcatheter (Hexacath, Paris, France).
IMR measurement
IMR measurement by thermodilution using the St Jude pressure guide.

Locations

Country Name City State
France APHP, Lariboisière Hospital, Cardiology Department Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absolute coronary resistance Threshold value correlated with microvascular obstruction on magnetic resonance imaging (MRI) Immediately after angioplasty
Primary Microvascular obstruction on MRI Establishment of a correlation between absolute coronary resistance and microvascular obstruction on MRI Day 7
Secondary Index of microvascular resistance Threshold value correlated with microvascular obstruction on MRI Immediately after angioplasty
Secondary Mean value of absolute coronary resistances corresponding to an IMR > 40 Establishment of a relationship between absolute coronary resistances and IMR Immediately after angioplasty
Secondary Microvascular obstruction in patients with IMR > 40 Establishment of a correlation between an IMR> 40 and the presence and the degree of microvascular obstruction as meaasured by cardiac MRI of the of infarcted area Day 7
Secondary Absolute coronary resistance indexed to the myocardial mass Establishment of a correlation between the indexed absolute coronary resistance and the presence and the degree of microvascular obstruction on cardiac MRI Immediately after angioplasty
Secondary IMR indexed to the myocardial mass Establishment of a correlation between the indexed IMR and the presence and the degree of microvascular obstruction on cardiac MRI Immediately after angioplasty
Secondary Occurrence of early ventricular rhythm disorders Establishment of a correlation between the absolute coronary resistances and IMR and the early ventricular rhythm disorders Day 3
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT04951856 - Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI Phase 4
Terminated NCT04459299 - CorPath GRX STEMI Study
Recruiting NCT05557019 - Semi Occlusion of the Coronary Sinus as an Adjunct to PCI in STEMI Patients, FIH Clinical Study N/A
Completed NCT03527940 - Prognostic Markers of Patients With STEMI
Not yet recruiting NCT03264859 - NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction N/A
Not yet recruiting NCT03182855 - Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI Phase 4
Not yet recruiting NCT03266289 - Evaluation of Short Term Outcome of Different Bifurcation Stenting Techniques at Assuit University Cath. Lab N/A
Withdrawn NCT04566289 - Observational Registry to Evaluate Real World Usage of PiCSO Impulse System in STEMI Patients as Part of Post-marketing Surveillance
Completed NCT04289012 - HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study N/A
Not yet recruiting NCT04185077 - Bivalirudin in Late PCI for Oatients With STEMI Phase 4
Completed NCT03609346 - Asian Registry of the BioFreedom Stent for STEMI Patients
Recruiting NCT05107076 - Effect of PPCI on Diastolic Function & Levels of Galactin-3 in Patients With STEMI
Recruiting NCT02998853 - Non Culprit Functional Evaluation With 3D Angio QFR in STEMI PCI Procedure N/A
Completed NCT03677180 - National Cardiogenic Shock Initiative
Completed NCT03507777 - ILUMIEN IV: OPTIMAL PCI N/A
Recruiting NCT03863327 - EKG Criteria and Identification of Acute Coronary Occlusion
Completed NCT03070496 - Multicenter Cohort of STEMI Patients N/A
Active, not recruiting NCT03874338 - CLEAR SYNERGY Neutrophil Substudy
Withdrawn NCT05497011 - A Study to Evaluate the Safety and Efficacy of PiCSO in Anterior STEMI Patients N/A